A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes

A closed-loop system (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes. In this 16-week trial, the glucose level was in the target range for a greater percentage of time with a closed-loop system than with a sensor-augmented insulin pump.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-08, Vol.383 (9), p.836-845
Hauptverfasser:	Breton, Marc D, Kanapka, Lauren G, Beck, Roy W, Ekhlaspour, Laya, Forlenza, Gregory P, Cengiz, Eda, Schoelwer, Melissa, Ruedy, Katrina J, Jost, Emily, Carria, Lori, Emory, Emma, Hsu, Liana J, Oliveri, Mary, Kollman, Craig C, Dokken, Betsy B, Weinzimer, Stuart A, DeBoer, Mark D, Buckingham, Bruce A, Cherñavvsky, Daniel, Wadwa, R. Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Age Automation Blood Glucose Blood Glucose - analysis Child Children Closed loop systems Diabetes Diabetes mellitus (insulin dependent) Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetic Ketoacidosis Diabetic Ketoacidosis - etiology FDA approval Female Glucose Glycated Hemoglobin A Glycated Hemoglobin A - analysis Hemoglobin Human health and pathology Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemic Agents Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Infusion Pumps, Implantable Injections, Subcutaneous Insulin Insulin - administration & dosage Insulin - adverse effects Insulin Infusion Systems Insulin Infusion Systems - adverse effects Ketoacidosis Kidney diseases Laboratories Life Sciences Male Pancreas Pancreas, Artificial Patients Quality of life Statistical analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A closed-loop system (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes. In this 16-week trial, the glucose level was in the target range for a greater percentage of time with a closed-loop system than with a sensor-augmented insulin pump.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2004736